For intended parents who carry a family history of genetic disease or chromosomal abnormalities, In Vitro Fertilization (IVF) technology is more than just a path to conception; it is the hope of blocking the disease's transmission to the next generation. By combining it with a Mexico surrogacy plan, modern reproductive medicine can offer precise genetic screening services, significantly reducing the risk of having an affected baby. This technology is known as Preimplantation Genetic Testing (IVF-PGT, formerly called third-generation IVF), which completes the most critical disease prevention work before the embryo is implanted.

 IVF-PGT: The Scientific Tool for Blocking Genetic Disease Transmission

IVF-PGT technology is a unique advantage of the IVF process, allowing physicians to conduct a genetic health assessment of the embryo before it is transferred to the surrogate's uterus.

1.  PGT-M: For Single-Gene Disorders

    For families carrying a known single-gene disorder (such as Thalassemia, Cystic Fibrosis, Spinal Muscular Atrophy - SMA, etc.), PGT-M (Preimplantation Genetic Testing for Monogenic disorders) is key.

     Principle: Doctors take a small sample of cells from the IVF-cultured embryo for testing, excluding embryos that carry the pathogenic gene mutation.

     Effect: This ensures that only healthy embryos or those not carrying the disease-causing gene are selected for the subsequent Mexico surrogacy embryo transfer, fundamentally preventing the transmission of the genetic disease.

2.  PGT-SR: For Chromosomal Structural Rearrangements

    For families where one or both partners have a chromosomal structural abnormality (such as balanced translocation, Robertsonian translocation, etc.), although they are phenotypically normal, their germ cells are more likely to produce aneuploid (chromosomal number or structural abnormality) embryos, leading to recurrent miscarriage or the birth of affected infants.

     Role: PGT-SR identifies these structurally abnormal embryos, significantly increasing the surrogacy implantation success rate and reducing the risk of miscarriage and birth defects.

3.  PGT-A: The Foundation for Optimal Birth Outcomes

    Even without a known history of genetic disease, PGT-A (Preimplantation Genetic Testing for Aneuploidy) is often used in IVF cycles.

     Purpose: To screen the embryo for aneuploidy (such as the common chromosomal number abnormalities like Down Syndrome).

     Advantage: This ensures that the embryo transferred to the Mexico surrogacy surrogate's uterus is chromosomally normal, which not only enhances the surrogacy success rate but is also an important safeguard for achieving optimal birth outcomes.

In recent years, with the continuous advancement of IVF technology, a growing body of research and clinical data supports the application of genetic testing in assisted reproduction. This provides not only a safer option for families who wish to prevent the transmission of genetic diseases to the next generation but also greater assurance for the success of IVF.

Power Fertility Center bridges U.S. and Mexico as a top fertility destination, powered by Power IVF’s elite clinical network. With premier labs in both regions, it offers full-spectrum fertility services—IVF, IUI, U.S. egg freezing, sperm freezing, egg donation, and surrogacy—catering to singles, married couples, and LGBTQ individuals. Power IVF provides IVF-PGT to Thailand, Taiwan, and more. Blending high-tech facilities with personalized care, its Mexico-based Guarantee Program ensures live births using egg donation and surrogacy, delivering high success and constant support for fertility preparation.